03.12.15
WuXi PharmaTech is building a new, 145,000-sq.-ft. cGMP facility in Philadelphia for the manufacture of cell therapies. This facility will contain viral vectors such as chimeric antigen receptor T cell (CAR T cell) therapies, which are T cells harvested from a patient's body, engineered to target specific cancers, and then reintroduced into the body. The company currently has a facility for biological safety and lot release testing in Philadelphia.
This will be WuXi's third cell therapy manufacturing facility when operational in mid-2016. It will provide contract development and cGMP manufacturing capabilities for clinical studies and commercial supply to support industry's unique requirements in this growing area. By 2016, WuXi will have 206,000 sq.-ft. of manufacturing capacity in the U.S. for clinical and commercial production of cell therapies.
"Cell therapies like CAR T cells offer important new treatment options for cancer patients, and WuXi aims to be at the forefront of this area of providing our partners with cutting-edge cGMP manufacturing capabilities and capacities," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.
This will be WuXi's third cell therapy manufacturing facility when operational in mid-2016. It will provide contract development and cGMP manufacturing capabilities for clinical studies and commercial supply to support industry's unique requirements in this growing area. By 2016, WuXi will have 206,000 sq.-ft. of manufacturing capacity in the U.S. for clinical and commercial production of cell therapies.
"Cell therapies like CAR T cells offer important new treatment options for cancer patients, and WuXi aims to be at the forefront of this area of providing our partners with cutting-edge cGMP manufacturing capabilities and capacities," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.